FINWIRES · TerminalLIVE
FINWIRES

$KMTS

8 stories mentioning KMTSUpdated 7d ago

Every FINWIRES story that references KMTS, newest first.

What are analysts saying about KMTS?

Recent broker actions mentioned in FINWIRES coverage. Compiled from wire headlines; not investment advice.

What's the latest news on KMTS?

Equities

Top Premarket Decliners

Enova International (ENVA) shares were down 15% in premarket activity Tuesday after the company withdrew its applications with the Office of the Comptroller of the Currency and the Board of Governors of the Federal Reserve System for the proposed acquisition of Grasshopper Bancorp.Dave & Buster's Entertainment (PLAY) stock was 11% lower after the company swung to a fiscal Q2 non-GAAP net loss.Stewards (SWRD) shares are down 10% after the company said it has continued to advance due diligence and discussions over the proposed acquisitions of PIXL at Plantation and Envy Pompano Beach.Kestra Medical Technologies' (KMTS) stock was 9% lower after the company reported a wider-than-anticipated fiscal Q1 net loss.Mach Natural Resources (MNR) shares were down 8% after a 0.6% loss in the prior session.

$ENVA$KMTS$MNR$PLAY$SWRD
Research

JPMorgan Initiates Kestra Medical Technologies at Overweight With $30 Price Target

Kestra Medical Technologies (KMTS) has an average rating of buy and mean price target of $30, according to analysts polled by FactSet.

$KMTS
Insider Trading

Kestra Medical Technologies Insider Sold Shares Worth $1,272,588, According to a Recent SEC Filing

Brian Daniel Webster, Director, President and Chief Executive Officer, on August 04, 2026, sold 51,900 shares in Kestra Medical Technologies (KMTS) for $1,272,588. Following the Form 4 filing with the SEC, Webster has control over a total of 475,215 common shares of the company, with 475,215 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1877184/000119312526338657/xslF345X05/ownership.xml

$KMTS
Wire

Kestra Medical's Bullish Fundamentals Driven by Large Total Addressable Market, Sustained Share Gains, Oppenheimer Says

Kestra Medical Technologies' (KMTS) bullish fundamentals are driven by a large total addressable market in the US, sustained share gains, and technology enhancements, Oppenheimer said in a Tuesday research note.The brokerage said it is seeking a better risk-reward entry point as share gains look priced into the stock, and true clinical differentiation of wearable cardiac defibrillators is difficult due to a lack of head-to-head trials.Analysts noted that their constructive view arises from the potential for the company's Assure wearable cardiac defibrillator to become a theranostics platform with multiple revenue drivers over time.The brokerage said it initiated coverage of the stock with a perform rating.Price: $23.00, Change: $-0.24, Percent Change: -1.03%

$KMTS
Research

Oppenheimer Initiates Kestra Medical at Market Perform

Kestra Medical (KMTS) has an average rating of buy and mean price target of $30, according to analysts polled by FactSet.

$KMTS
Insider Trading

Kestra Medical Technologies Insider Sold Shares Worth $336,609, According to a Recent SEC Filing

Brian Daniel Webster, Director, President, and Chief Executive Officer, on July 15, 2026, sold 15,000 shares in Kestra Medical Technologies (KMTS) for $336,609. Following the Form 4 filing with the SEC, Webster has control over a total of 556,937 common shares of the company, with 556,937 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1877184/000119312526308041/xslF345X05/ownership.xml

$KMTS
Insider Trading

Kestra Medical Technologies Insider Sold Shares Worth $312,143, According to a Recent SEC Filing

Brian Daniel Webster, Director, President and CEO, on June 15, 2026, sold 15,000 shares in Kestra Medical Technologies (KMTS) for $312,143. Following the Form 4 filing with the SEC, Webster has control over a total of 395,467 common shares of the company, with 395,467 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1877184/000119312526274257/xslF345X05/ownership.xml

$KMTS
Insider Trading

Kestra Medical Technologies Insider Sold Shares Worth $300,671, According to a Recent SEC Filing

Brian Daniel Webster, Director, President and Chief Executive Officer, on April 15, 2026, sold 15,000 shares in Kestra Medical Technologies (KMTS) for $300,671. Following the Form 4 filing with the SEC, Webster has control over a total of 349,786 common shares of the company, with 349,786 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1877184/000119312526159276/xslF345X05/ownership.xml

$KMTS

Track with the FINWIRES app suite

FolioX
FolioX
Track KMTS in your portfolio
WheelAI
WheelAI
Analyze KMTS options with the wheel strategy
StockInsider
StockInsider
See market sentiment on KMTS